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1  Introduction
Acute toxicity refers to adverse effects occurring following a 
single exposure to a substance or following multiple exposures 
within 24 hours. In the area of regulatory toxicology, acute tox-
icity studies are the longest standing class of toxicity test, dat-
ing back to the “lethal dose 50 percent” method developed by 
trevan (1927). However, the use of lethality as an endpoint has 
long been a subject of controversy on both ethical/animal wel-
fare and scientific grounds (Balls, 1991; Robinson et al., 2008; 
Seidle et al., 2010). Pharmaceutical companies have stated that 
“these studies have limited value in terms of pre-clinical and 
human safety assessment compared to the substantial adverse 
effects experienced by some of the animals” (Robinson et al., 
2008), and this sector itself has recently moved to discontinue 
the routine requirement for stand-alone acute toxicity studies 
(ICH, 2009). Systemic acute toxicity studies nonetheless remain 
a common feature in a number of regulatory frameworks and 
voluntary initiatives, such as high production volume (HPV) 
chemicals programs. Available statistics indicate that more ani-
mals have been used in recent years in assessment of this end-
point than in any other single area of toxicology (eC, 2007). 
In certain sectors, regulatory information requirements pre-
scribe testing for acute toxicity by up to three different exposure 
routes (oral, dermal, inhalation), and in some cases, for both 
individual substances/ingredients and formulated products/arti-
cles. this generally is the case for agricultural and plant protec-
tion chemicals and biocidal products (collectively referred to as 
“pesticides”) due to their intended biological activity and toxic 
mode of action, as well as the potential for human exposure via 
multiple routes (e.g., oral ingestion of residues on food; poten-
tial dermal and/or inhalation exposure during the application 
process, and in other occupational scenarios). Requirements for 
industrial chemicals are more variable from country to country 
but in certain cases may also prescribe acute systemic toxicity 
testing by more than one exposure route. For example, the Reg-
istration, evaluation, Authorisation and Restriction of Chemi-
cals (ReACH) regulation in the european Union (eU) requires 
single-route acute toxicity data for all substances manufactured 
or imported in volumes of more than one metric ton per annum 
(tpa), and data for a second route for substances in the ≥10 tpa 
band (OJ, 2007). A detailed review of regulatory requirements 
and other drivers for acute toxicity test data across industry sec-
tors and major international markets has been published else-
where (Seidle et al., 2010). 
A key finding of the aforementioned review is that the prin-
cipal use of acute toxicity data is to support regulatory classifi-
cation and hazard labeling decisions (although it is recognized 
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GHS and its most common variants in use in Australia, Canada, 
and the eU (OJ, 2008), as well as the former eU scheme under 
the Dangerous Substances Directive (OJ, 1967), and schemes 
used by United States agencies charged with worker protection 
(OSHA, 2009) and the regulation of consumer products (CP-
SC, 1973) and pesticides (ePA, 2004). A key difference among 
these schemes is the prescribed limit dose (i.e., 2,000 mg/kg 
or 5,000 mg/kg), beyond which a substance is not required to 
bear a hazard label for acute toxicity. the GHS designates test-
ing beyond 2000 mg/kg as optional and discouraged on animal 
that these data can also be used to derive safe use threshold lev-
els, e.g., Derived No effect level (DNel) or Acute exposure 
Guideline Level (AEGL)). Frameworks for classification and 
labeling differ somewhat among countries/regions, and some-
times among authorities within the same country. the Globally 
Harmonized System of Classification and Labeling of Chemicals 
(GHS) was developed under the auspices of the United Nations 
(UN, 2007) to promote increased regulatory consistency and ef-
ficiency among countries and sectors. Figure 1 illustrates the 
different hazard class cut-offs for acute oral toxicity between the 
Fig. 1: Comparison of hazard classification schemes for acute oral toxicity
Fig. 2: Comparison of hazard classification schemes for acute dermal toxicity
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fied for acute dermal toxicity, and for only one of these did the 
dermal study lead to a more severe classification than the oral 
study. In 2007, the UK Pesticide Safety Directorate (thomas 
and Dewhurst, 2007) examined unpublished acute oral and der-
mal toxicity data for 195 pesticide active ingredients and 3,111 
formulated products, concluding that the dermal study adds lit-
tle if anything to the database on pesticide active substances, 
and that a similar result was indicated for formulations. A more 
recent paper by Creton and colleagues (2010) arrived at the 
same conclusion following the review of a slightly expanded 
data set of pesticide active ingredients. this paper builds on the 
above analyses using a significantly expanded data set of in-
dustrial chemicals, as well as pesticide active ingredients from 
non-eU sources that have not been considered in the afore-
mentioned reviews. We also examine concordances among oral 
and inhalation route classifications, and consider the impact on 
our conclusions of the prevalence of positively and negatively 
classified substances within the database. This publication con-
tributes to the efforts of the Acute toxicity task Force of the 
european Partnership for Alternative Approaches to Animal 
testing (ePAA) to identify opportunities for application of the 
3Rs in this area.
2  Methods
2.1  Chemicals dataset
Data for industrial chemicals were obtained from the eU New 
Chemicals Database (NCB), a proprietary repository of toxicity 
information for all substances notified to European authorities 
since 1981 (i.e., from the entry into force of the sixth amend-
ment to the former eU Dangerous Substances Directive 67/548/
EEC). Substances exempted from notification include pesti-
cides, cosmetics, pharmaceuticals, foodstuffs, radioactive mate-
rials, wastes, and substances used in scientific research. When 
accessed on June 11, 2008, the NCD contained 7,812 notification 
welfare grounds (UN, 2007), and the US Occupational Safety 
and Health Administration (OSHA, 2009) adds that exposures 
of this magnitude are not likely to be encountered in the occu-
pational setting. For these reasons, countries adopting the GHS 
are for the most part adopting a 2,000 mg/kg limit dose for acute 
oral toxicity. Figures 2 and 3 compare selected classification 
schemes for acute dermal and inhalation toxicity.
Notwithstanding differences among national and sector-
specific classification systems, it is common to use the lowest 
available oral or dermal lethal dose (lD50) or inhalation le-
thal concentration (lC50) value to assign a substance or article 
to a hazard category (OJ, 2008), and label warnings normally 
reflect the most severe hazard category (UN, 2007; OSHA, 
2009). thus, if it were possible to identify an exposure route 
that is consistently more or less sensitive than another and is 
relevant to a particular exposure scenario, multi-route animal 
testing would not be necessary. the “3Rs” principle of replace-
ment, reduction, and refinement of animal use (Russell and 
Burch, 1959) is a longstanding tenet of sound science, and it 
seems especially apt in the case of toxicity studies that involve 
not only death as a primary endpoint in most cases but also 
testing of the same substance using multiple routes of exposure 
and/or species. In some parts of the world, the minimization of 
animal testing is a legal requirement, as exemplified by Article 
7.2 of eU Directive 86/609/eeC for the protection of animals 
used for experimental and other scientific purposes (OJ, 1986), 
and Article 13 of REACH, which specifies that hazard informa-
tion shall be generated whenever possible by means other than 
vertebrate animal tests. 
to date, a handful of retrospective reviews of acute oral and 
dermal toxicity classifications have been reported in the litera-
ture. In 1998, investigators from the UK Health and Safety ex-
ecutive (Indans et al., 1998) presented the results of an analysis 
of acute toxicity classifications for 438 industrial chemicals 
notified in the EU for the period 1984 to 1997. This analysis 
found that only four of these substances were positively classi-
Fig. 3: Comparison of hazard classification schemes for acute inhalation toxicity 
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without attempts at independent confirmation. Given the size 
of the database, it was considered that any overall conclusions 
would not be unduly confounded by an occasional error in the 
production of the summaries. When a range of lD/lC50 values 
was cited, the lowest value in the most relevant species (rodent 
or rabbit) and exposure scenario (e.g., 4-hour inhalation) was 
selected. In cases where the lowest lD/lC50 value was ob-
tained using a non-traditional species or one so taxonomically 
removed from rodents (e.g., non-human primates) as to call into 
question the validity of a concordance analysis, preference was 
given to the next lowest lD/lC50 value in rodents or rabbits. 
lD/lC50 values obtained from sources that reported any uncer-
tainty regarding data quality (e.g., inhalation studies in which 
maximum concentration was not achieved) were excluded from 
the analysis. 
the resulting database is comprised of 429 agrochemical and 
biocidal active substances representing major product types 
(antimicrobials and other biocides, biochemicals, fungicides, 
herbicides, defoliants and plant growth regulators, insecticides, 
repellants and fumigants, vertebrate control agents, etc.). All 
lD/lC50 values were converted to regulatory classifications 
according to GHS criteria (UN, 2007). In cases where it was 
unclear whether a test atmosphere consisted of aerosols (solid or 
liquid), vapors, or a combination of the two, classifications were 
made according to GHS criteria for aerosols as recommended 
by Pauluhn et al. (1996). As above, substances with oral and 
dermal lD50 values in excess of 2,000 mg/kg were considered 
for the purposes of this analysis as being “non-classified” for 
acute toxicity. this analysis has purposely excluded substances 
already examined by Creton et al. (2010). In total, concordance 
assessments are based on 337 substances that have been tested 
by both oral and dermal routes, and 348 tested by both oral and 
inhalation routes. the substances used for the concordance as-
sessments are listed in a supplementary data file on www.altex-
editon.org.
3  Results and discussion
3.1  Oral-dermal concordance
the relationship between acute oral and dermal toxicity clas-
sifications is summarized in Tables 1 and 2. For chemicals, the 
overall concordance among oral and dermal lD50 classifica-
tions was 93.7% across 1,569 substances. the oral and dermal 
route concordance for non-classified substances is 100%. The 
dermal test resulted in a more severe classification in only one 
instance (0.06% – classified as orally hazardous but dermally 
toxic), while the oral test yielded positive classifications for 98 
substances (6.2%) that would have been underclassified by a 
dermal test alone. Of these, 88 were classed as hazardous, nine 
as toxic, and one as highly toxic. 
For pesticides, the overall oral-dermal concordance was 54% 
across 337 substances (tab. 2). For an additional 148 substanc-
es (43.92%) the oral test yielded more severe classifications, 
while the dermal test proved to be more sensitive in six cases 
(1.78%). Had the oral lD50 value alone been used as a basis 
for classification, the pesticides Furfural, Kelevan, Methyli-
dossiers, representing 4,946 substances notified in Europe since 
1981. For the analysis performed in this study, all substances 
were included that possessed a classification after acute sys-
temic exposure in rats via oral, dermal and/or inhalation routes 
(3,317 in total). Substances excluded were those for which the 
lD/lC50 values reported were not consistent with the classifica-
tion (e.g., an oral lD50 >800 mg/kg being designated “non-clas-
sified”). Of the 3,317 substances with acute toxicity data for at 
least one relevant exposure route, 1,990 (60%) also were tested 
by a second route, including 1,737 substances with both oral 
and dermal data and 81 substances with both oral and inhala-
tion data. Following the application of exclusion criteria, a total 
of 1,569 substances were used for the oral-dermal concordance 
assessment, and 71 substances were used for determining oral-
inhalation concordance. 
Regulatory classifications listed in the NCB are based on 
the now historic eU Dangerous Substances Directive (DSD) 
scheme (since superseded by eU Regulation 1272/2008 on 
Classification, Labeling and Packaging of Substances and Mix-
tures (ClP; OJ, 2008). A decision against converting individual 
classifications from the four category DSD system to the up 
to 5-6 category GHS scheme (see Fig. 1-3) was made on the 
basis that most dermal studies (97%) were conducted as limit 
tests using a 2,000 mg/kg cutoff, which precludes a direct com-
parison against oral studies in which dosing up to or beyond 
5,000 mg/kg was performed. As such, substances with oral and 
dermal lD50 values in excess of 2,000 mg/kg are considered 
for the purposes of this analysis as being “non-classified” for 
acute toxicity.
2.2  Pesticides dataset
Data for agrochemical and biocidal active ingredients were 
obtained through systematic reviews of the following publicly 
accessible online databases and information repositories main-
tained by regulatory authorities and intergovernmental bodies: 
Working Documents of the eC Standing Committee on the Food 
Chain and Animal Health in view of the inclusion of plant pro-
tection active substances in Annex I of Directive 91/414/eeC 
(eC, 2009a; eC, 2009b) Assessment Reports concerning inclu-
sion of biocidal active substances in Annex I or IA to Directive 
98/8/eC; european Food Safety Authority (eFSA, 2009) Draft 
Assessment Reports for plant protection active substances; US 
environmental Protection Agency (ePA, 2009; 2010) Reregis-
tration eligibility Decision documents and Fact Sheets on new 
active ingredients; and the International Program on Chemical 
Safety (IPCS, 2009) INCHeM database. lD/lC50 values were 
collected if available for at least two of the three relevant expo-
sure routes (oral, dermal, inhalation) using mammalian species 
and procedures specified in current Organization for Economic 
Cooperation and Development (OeCD, 2009) test guidelines, 
together with CAS registry number, broad product type (e.g., 
antimicrobial, insecticide), and physical state descriptor. In the 
case of regulatory decision documents, only a single value was 
normally reported for each exposure route, which may reflect a 
pre-selection by authorities of the (generally lowest) lD/lC50 
value from among two or more possible choices. the lD/lC50 
values in the summary documents were taken at face value 
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sothiazolinone, Mirex and Sodium Cyanide would have been 
underclassified by a single category, while Dowicil®CtAC 
(classified dermally as GHS Category 3) would have been un-
classified. In the case of Sodium Cyanide (classified orally as 
GHS Category 2 and dermally as Category 1), the underclas-
sification appears to be GHS-specific, i.e., the oral LD50 of 7.5 
mg/kg is just above the 5 mg/kg threshold for inclusion in Cat-
egory 1. this discordance would not have occurred under the 
former DSD scheme or if the US ePA or CPSC schemes had 
been used (Fig. 1), with their Category 1 thresholds of 25 mg/
kg and 50 mg/kg, respectively. Furthermore, from a hazard-
labeling standpoint (relevant for the protection of workers who 
may be directly exposed to pesticidal active substances), clas-
sification in GHS Category 2 as opposed to Category 1 has no 
impact on label signal word or hazard statement. For Furfural, 
Kelevan and Methylisothiazolinone (all oral Category 3/dermal 
Category 2), the signal word “danger” would still be present for 
all substances, although the hazard statement would be down-
graded from “fatal in contact with skin” to “toxic in contact 
with skin” for a Category 3 classification. For Mirex (oral Cat-
egory 4/dermal Category 3), both signal word and hazard state-
ment would be downgraded, i.e., from “danger” to “warning” 
and from “toxic” to “harmful,” respectively. Dowicil®CtAC is 
the only substance that would have been overlooked entirely 
based on oral data (and a 2,000 mg/kg limit dose), whereas der-
mal results would have led to a GHS Category 3 classification 
and concomitant “danger” and “toxic” label statements, with 
advice that workers wear chemical-resistant gloves for open-
pouring of the end-use product (ePA, 2007). the reasons be-
hind the relatively greater sensitivity of the dermal route in this 
case are not clear at this time, in part due to the lack of dermal 
penetration studies in the database. Dowicil is considered to be 
a non-sensitizer based on a guideline study in guinea pigs. In 
a rabbit dermal irritation study, Dowicil produced only a slight 
edematous reaction on intact skin, resulting in a “slight irritant” 
label under the US EPA pesticide classification scheme; how-
ever, under the eU ClP scheme, the substance would not be 
considered a dermal irritant (ePA, 2004; OJ, 2008). the magni-
tude of the discordance in acute systemic classification results 
for Dowicil appears, to some extent, also to be classification 
scheme-specific, i.e., it would not have been as pronounced un-
der the US pesticides scheme.
On the whole, these analyses illustrate the limited value of 
acute systemic toxicity testing via the dermal route for the pur-
pose of classification and labeling, which is the primary driver 
for such studies (Seidle et al., 2010), thus calling into question 
the appropriateness of regulations that continue to require re-
dundant dermal route testing when oral data are already avail-
able. the extent to which dermal acute data provide added 
value for the regulation of formulated preparations/articles is 
also questionable (thomas and Dewhurst, 2007) and warrants 
further investigation. 
In the context of chemical regulation in the eU, table 3 
shows the distribution of substances registered in the NCD 
through June 2008 according to the two levels of information 
requirements established by ReACH for acute systemic toxic-
ity, i.e., annual production volume ≥1 metric ton (Annex VII) 
and annual production ≥10 metric tons (Annex VIII). Based 
on their production volume, 25% of all substances registered 
Tab. 1: Concordance among oral and dermal route acute 
toxicity classifications for industrial chemicals  
in the EU New Chemicals Database according to  
the former EU DSD scheme
 ORAL
DERMAL NC Xn  T  T+
NC 1460 88  9  1
Xn    0 10  0  0
T    0  1  0  0
T+    0  0  0  0
* NC = no classification required; Xn = harmful; T = toxic; T+ = very toxic
Tab. 2: Concordance among oral and dermal route acute 
toxicity classifications for pesticide active substances 
according to the GHS (without the optional Category 5)
 ORAL
DERMAL NC  4  3  2  1
NC 154 96 32  2  2
4   0  6  4  2  0
3   1  1  9  6  2
2   0  0  3  4  2
1   0  0  0  1 10
Tab. 3: Distribution of substances listed in the EU New Chemicals Database through June 2008 with acute oral and  
dermal toxicity data according to REACH tonnage bands
 All substances registered  Substances with oral and
 in NCD (June 2008) dermal toxicity data (June 2008)
Substances manufactured or imported  25% 41%in quantities ≥1 tpa
Substances manufactured or imported  43% 53%in quantities ≥10 tpa
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discordance could be an artifact of the classification system it-
self. As illustrated in Figure 3, criteria for making acute inha-
lation classifications differ considerably among countries and 
sectors. Differences include both the lC50 thresholds that de-
fine individual classification categories, as well as the fact that 
some systems establish separate criteria for aerosols (solid and 
liquid) versus vapors and gases while others do not. For exam-
ple, the lC50 dose range for an inhalation Category 1 classifica-
tion under the US pesticides scheme is quite narrow, i.e., up to 
0.05 mg/l for all substances, regardless of their physical state. 
the same range is used under the GHS for dusts and mists; how-
ever, for vapors the upper threshold for a Category 1 classifica-
tion is tenfold higher, i.e., 0.5 mg/l, whereas the US pesticides 
scheme has established this dose level as the upper threshold 
for a Category II classification. Similarly, the dose range for a 
GHS Category 2 classification for vapors is identical to the US 
pesticide Category III, while vapors classified as Category IV 
under the US scheme would be classified as Category 3 under 
the GHS. Differences of comparable magnitude also would be 
evident if GHS classifications were compared against those of 
the former EU DSD scheme. Thus, depending on the classifica-
tion scheme used, physical state of the substance in question 
and whether it is deemed to be predominantly mist or vapor 
over the course of a test, acute inhalation classifications could 
easily diverge by at least one severity category among GHS, 
in the NCD fall within the ReACH Annex VII requirement for 
a single-route (usually oral) acute toxicity study, while 43% of 
substances fall within the Annex VIII requirement for a second 
acute study (dermal or inhalation, depending on the nature of the 
substance and the likely route of human exposure). It is signifi-
cant to note the relative prevalence of high-tonnage substances 
in the NCD, as well as the fact that nearly half of these (47%) 
appear not to possess acute toxicity data for more than one ex-
posure route. thus, a regulatory decision to waive the require-
ment for an acute dermal study for the estimated 10,000 exist-
ing substances that will be subject to ReACH Annex VIII data 
requirements could potentially spare a large number of animals 
(assuming that dermal testing has not already been carried out, 
or that an inhalation study is not simply substituted in place of 
the dermal test; see 3.2. for additional discussion of this point). 
With regard to pesticides, we note that at the time of this writ-
ing, eU data requirements for agrochemicals are undergoing re-
vision, as are regulations governing the registration of biocides 
in the eU and antimicrobial pesticides in the US. A review and 
reconsideration of data requirements for dermal acute systemic 
toxicity would therefore be both timely and warranted in these 
regions and elsewhere. In relation to formulated pesticide prod-
ucts, the EU’s longstanding acceptance of “classification by 
calculation”, i.e., pursuant to Annex II of the former Directive 
1999/45/eC, which has recently been replaced by Regulation 
(eC) No 1272/2008, could obviate the conduct of redundant in 
vivo testing of formulations comprised of well characterized ac-
tive substances and other ingredients (OJ, 1999; 2008). 
3.2  Oral-inhalation concordance
the relationship between acute oral and inhalation toxicity 
classifications is summarized in Tables 4 and 5. For chemicals, 
the overall concordance among oral lD50 and inhalation lC50 
classifications was 71.8% across 71 substances. The oral test 
resulted in a more severe classification in eight cases (11.3%, 
classified as orally hazardous but unclassified by the inhalation 
route), while the inhalation test yielded positive classifications 
for nine substances (6.2%) that would have been unclassified 
based on oral findings, and a further three substances (4.2%) 
that would have been underclassified by one or more DSD cat-
egories. 
For pesticides, the oral-inhalation concordance was markedly 
lower: 24.12% across 348 substances classified according to 
GHS criteria (tab. 5). For an additional 23.85% of substances, 
the oral test resulted in a more severe classification, whereas 
inhalation data led to a more severe classification for 51.72% 
of substances examined. Active substances classified as GHS 
Category 1 via inhalation but unclassified orally include 
Acequinocyl, Ammonium thiosulfate, Bifenox, Bromacil, 
Bupirimate, Buprofezin, Clofencet, Cyflufenamid, Dichlobenil, 
Diflufenzopyr, Disodium tetraborate, Mesotrione, Metrafenone, 
Pine Oil, Piperonyl Butoxide, and Sintofen. Further investiga-
tion is needed to identify the physico-chemical (reactivity, par-
ticle size, vapor pressure, solubility), kinetic, metabolic, and 
other factors that underlie differences seen in acute toxic re-
sponses following oral and inhalation exposure (Pauluhn et al., 
1996). It is possible, however, that at least some of the observed 
Tab. 4: Concordance among oral and inhalation route  
acute toxicity classifications for industrial chemicals  
in the EU New Chemicals Database according to the  
former EU DSD scheme
 ORAL
INHALATION NC Xn  T  T+
NC  50  8  0  0
Xn   4  1  0  0
T   3  1  0  0 
T+   2  1  1  0
* NC = no classification required; Xn = harmful; T = toxic; T+ = very toxic
Tab. 5: Concordance among oral and inhalation route acute 
toxicity classifications for pesticide active substances 
according to the GHS (without the optional Category 5)
 ORAL
INHALATION NC  4  3  2  1
NC  36  23 17  2  3
4  53  38 17  6  8
3  29  17  7  4  2
2  23  17  7  3  1
1  16  11  4  3  0
altex_2011_2_095_102_Seidle.indd   100 15.5.2011   21:05:23 Uhr
Seidle et al.
Altex 28, 2/11 101
3. Data requirements prescribing acute dermal systemic testing 
of formulated agrochemical and biocidal products and well-
characterized mixtures should be reconsidered in light of 
data presented and the established and conservative practice 
of classification by calculation.
4. It is important to avoid the situation under ReACH whereby 
inhalation becomes the default second route for acute testing 
for substances in the ≥10 tpa tonnage band (by process of 
elimination if dermal testing is discontinued). Opportunities 
for refinement or expansion of existing criteria for adaptation 
or waiving of acute inhalation study requirements for chemi-
cals should be fully explored.
5. Further investigation is needed to identify the physico-
chemical, kinetic, metabolic, and other factors that underlie 
differences seen in acute toxic responses following oral and 
inhalation exposure.
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Criteria currently specified in REACH technical guidance in-
clude knowledge of local toxicity, low volatility (i.e., vapor 
pressures <1 x 10-5 and <1 x 10-4 for indoor and outdoor uses, 
respectively), molecular weight, particle size (particles larger 
than 100 μm are less likely to be inhalable), mass median aer-
odynamic diameter, water solubility, reactivity, and ability to 
generate a stable test atmosphere (eCHA, 2008; Pauluhn et al., 
1996). Waiving would not be envisioned in the case of highly 
acutely toxic substances for which derivation of an acute DNel 
or AeGl is necessary. It may also be prudent to re-examine clas-
sification criteria for acute inhalation toxicity (i.e., LC50 cut-offs 
between categories) to verify the consistency of severity catego-
ries across exposure routes (e.g., that the severity of effects seen 
in an inhalation Category 2 are reasonably comparable to those 
of oral or dermal classifications of the same magnitude). 
4  Conclusions and recommendations
Our analysis provides further, compelling evidence that dermal 
acute systemic toxicity data almost never drive regulatory classi-
fication and labeling decisions in the chemicals, agrochemicals, 
or biocides sectors. thus, their contribution to the protection of 
consumers and workers would appear to be marginal at best and 
insufficient to warrant the routine conduct of redundant, lethal 
in vivo studies. We therefore recommend the following:
1. Dermal acute systemic testing should not be required for 
substances that are non-classified by the oral route, since the 
data clearly show that the oral route is almost always more 
sensitive, and the concordance among oral and dermal routes 
for non-classified substances is 100% for industrial and agro-
chemicals and 99.4% for biocides. Relevant national/region-
al data requirements for all three classes of substances should 
be revised accordingly (i.e., deleted or downgraded to condi-
tional requirements) together with applicable implementing 
guidance. 
2. Before a new dermal acute toxicity study is carried out, an 
in vitro dermal absorption/penetration study (OeCD, 2004) 
should be conducted to assess the likely magnitude and rate 
of dermal bioavailability. 
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